Clinical characteristics and symptom duration among outpatients with COVID-19.
Ambulatory care
Coronavirus infections
Outpatients statistics and numerical data
Recovery of function
Risk factors
Journal
American journal of infection control
ISSN: 1527-3296
Titre abrégé: Am J Infect Control
Pays: United States
ID NLM: 8004854
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
20
08
2021
revised:
26
10
2021
accepted:
27
10
2021
pubmed:
16
11
2021
medline:
6
4
2022
entrez:
15
11
2021
Statut:
ppublish
Résumé
Approximately 80% of people with COVID-19 do not require hospitalization. Studies examining the outpatient experience have not tracked symptoms to resolution leading to unknown expected symptom duration. Our objectives were to (1) determine symptom duration among patients with COVID-19 who do not require hospitalization and (2) identify potential risk factors associated with prolonged symptom duration. This is a retrospective cohort study conducted across an academic healthcare system including adult patients with laboratory-confirmed SARS-CoV-2 infection between March 18th and April 28th, 2020 who were not hospitalized. Symptom duration encompassed time from patient-reported symptom onset as documented in the chart until documented symptom resolution. We calculated the median symptom duration and tested if demographics, comorbidities, or reported symptoms were associated with symptom duration. Of 294 patients meeting inclusion criteria, 178 (60.5%) had documented symptom resolution. The median [interquartile range (IQR)] symptom duration for included patients was 15 (8-24) days. No associations were found between comorbidities and symptom duration. Factors associated with prolonged symptom duration were presence vs lack of lower respiratory symptoms [median (IQR) 16.5 (10.75-33.5) vs 14.5 (7-21.75) days respectively, P < .001] and neurologic symptoms [median (IQR) 17 (9-28) vs 9.5 (4-17) days, P < .001] at disease onset. The median symptom duration in outpatients is 15 days and over 25% of patients have symptoms longer than 21 days.
Sections du résumé
BACKGROUND
Approximately 80% of people with COVID-19 do not require hospitalization. Studies examining the outpatient experience have not tracked symptoms to resolution leading to unknown expected symptom duration. Our objectives were to (1) determine symptom duration among patients with COVID-19 who do not require hospitalization and (2) identify potential risk factors associated with prolonged symptom duration.
DESIGN
This is a retrospective cohort study conducted across an academic healthcare system including adult patients with laboratory-confirmed SARS-CoV-2 infection between March 18th and April 28th, 2020 who were not hospitalized. Symptom duration encompassed time from patient-reported symptom onset as documented in the chart until documented symptom resolution. We calculated the median symptom duration and tested if demographics, comorbidities, or reported symptoms were associated with symptom duration.
KEY RESULTS
Of 294 patients meeting inclusion criteria, 178 (60.5%) had documented symptom resolution. The median [interquartile range (IQR)] symptom duration for included patients was 15 (8-24) days. No associations were found between comorbidities and symptom duration. Factors associated with prolonged symptom duration were presence vs lack of lower respiratory symptoms [median (IQR) 16.5 (10.75-33.5) vs 14.5 (7-21.75) days respectively, P < .001] and neurologic symptoms [median (IQR) 17 (9-28) vs 9.5 (4-17) days, P < .001] at disease onset.
CONCLUSIONS
The median symptom duration in outpatients is 15 days and over 25% of patients have symptoms longer than 21 days.
Identifiants
pubmed: 34780804
pii: S0196-6553(21)00723-9
doi: 10.1016/j.ajic.2021.10.039
pmc: PMC8590478
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-389Informations de copyright
Copyright © 2021 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
Références
Medicine (Baltimore). 2021 Jun 18;100(24):e26371
pubmed: 34128896
Clin Microbiol Infect. 2020 Jul;26(7):948.e1-948.e3
pubmed: 32360780
BMJ. 2020 Feb 19;368:m606
pubmed: 32075786
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Am J Infect Control. 2020 Sep;48(9):1032-1036
pubmed: 32634536
Clin Infect Dis. 2020 Jul 28;71(15):807-812
pubmed: 32240285
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Diabetes Res Clin Pract. 2020 Aug;166:108299
pubmed: 32623030
Ann Emerg Med. 1996 Mar;27(3):305-8
pubmed: 8599488
Braz J Otorhinolaryngol. 2020 Sep - Oct;86(5):632-638
pubmed: 32561220
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Infect Dis. 2020 Jul 28;71(15):889-890
pubmed: 32215618
AJR Am J Roentgenol. 2020 Aug;215(2):367-373
pubmed: 32223665
J Korean Med Sci. 2020 Apr 06;35(13):e142
pubmed: 32242348
Nat Med. 2020 Jun;26(6):861-868
pubmed: 32327757
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA Otolaryngol Head Neck Surg. 2020 Aug 1;146(8):729-732
pubmed: 32614442
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Emerg Infect Dis. 2021;27(4):1164-1168
pubmed: 33754981
Ann Otol Rhinol Laryngol. 2021 May;130(5):513-519
pubmed: 33025798
JAMA. 2020 Mar 17;323(11):1092-1093
pubmed: 32031568
JAMA Netw Open. 2020 Dec 1;3(12):e2029058
pubmed: 33301018
J Med Virol. 2020 Nov;92(11):2758-2767
pubmed: 32544281
Ann Intern Med. 2007 Oct 16;147(8):W163-94
pubmed: 17938389
Clin Nurs Res. 2022 Nov;31(8):1390-1398
pubmed: 36154716
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
Aging (Albany NY). 2020 Jul 13;12(13):12493-12503
pubmed: 32658868
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Trop Dis Travel Med Vaccines. 2020 Aug 28;6:16
pubmed: 32868984
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386
pubmed: 32240123
Hum Vaccin Immunother. 2021 Apr 3;17(4):1109-1112
pubmed: 33079625
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
J Infect. 2020 May;80(5):e1-e6
pubmed: 32171869
Chin Med J (Engl). 2020 May 5;133(9):1032-1038
pubmed: 32118640
Aging (Albany NY). 2020 Apr 8;12(7):6049-6057
pubmed: 32267833
SN Compr Clin Med. 2020;2(9):1349-1357
pubmed: 32838186
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Acad Emerg Med. 2020 Jun;27(6):469-474
pubmed: 32396670
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):377-381
pubmed: 32240128
Open Forum Infect Dis. 2020 Jun 30;7(7):ofaa271
pubmed: 33117855
Infection. 2021 Apr;49(2):361-365
pubmed: 32410112
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
SN Compr Clin Med. 2021;3(1):247-254
pubmed: 33469566
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
BMJ Open. 2020 Sep 2;10(8):e040380
pubmed: 32878768
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202
BMC Infect Dis. 2021 Feb 25;21(1):221
pubmed: 33632171
J Family Med Prim Care. 2020 Oct 05;9(10):5360-5365
pubmed: 33409216
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Aging Dis. 2020 Jul 23;11(4):988-1008
pubmed: 32765959
JAMA Netw Open. 2021 Feb 1;4(2):e210830
pubmed: 33606031
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379
pubmed: 32242738
Int Forum Allergy Rhinol. 2020 Jul;10(7):821-831
pubmed: 32329222
Intern Emerg Med. 2020 Aug;15(5):813-817
pubmed: 32474850
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238